Missouri 2026 Regular Session Status: In Committee 4 D cosponsors

HB 2828 — Adds certain psychoactive substances to the list of Schedule I controlled substances and modifies the offenses of possession of a controlled substance and delivery of a controlled substance

Last action — HCS Reported Do Pass (H) - AYES: 12 NOES: 0 PRESENT: 0

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced January 07, 2026. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 42% · moderate confidence

  • In Committee

    Current position in the legislative process.

  • 4 sponsors

    1 primary, 3 co-sponsors signed on.

  • Single-party support

    Sponsorship is currently within one party (4 D).

  • Cleared a recorded vote

    Passed 1 recorded vote so far.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Bill Text

What changed in the latest version

702 added · 703 removed

Plain-language change summary

The revised version of Bill HB 2828 adds several substances to a list of controlled compounds, including Etoxeridine and various other synthetic drugs. It also removes Nitrous oxide from the list of substances considered dangerous. These changes are important because they reflect a growing awareness of new and potentially harmful drugs, aiming to enhance public safety by regulating more substances that could affect health and wellbeing.

→
Previous
Latest
SECOND REGULAR SESSION HOUSE BILL NO.
SECOND REGULAR SESSION HOUSE COMMITTEE SUBSTITUTE FOR HOUSE BILL NO.
2828 103RD GENERAL ASSEMBLY INTRODUCED BY REPRESENTATIVE FUCHS.
2828 103RD GENERAL ASSEMBLY 6157H.02C JOSEPH ENGLER, Chief Clerk AN ACT To repeal sections 195.017, 579.015, and 579.020, RSMo, and to enact in lieu thereof three new sections relating to psychoactive substances, with penalty provisions.
6157H.01I JOSEPH ENGLER, Chief Clerk AN ACT To repeal sections 195.017, 579.015, and 579.020, RSMo, and to enact in lieu thereof three new sections relating to psychoactive substances, with penalty provisions.
(f) Allylprodine;
HB 2828 2 (f) Allylprodine;
HCS HB 2828 2 (g) Alphacetylmethadol (except levoalphacetylmethadol, also known as levo-alpha- acetylmethadol levothadyl acetate or LAAM);
(g) Alphacetylmethadol (except levoalphacetylmethadol, also known as levo-alpha- acetylmethadol levothadyl acetate or LAAM);
(ff) Etoxeridine;
(ff)Etoxeridine;
HB 2828 3 (kk) Ketobemidone;
(kk) Ketobemidone;
(ll) Levomoramide;
HCS HB 2828 3 (ll) Levomoramide;
(rr) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
(rr)MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
(eee)Phenomorphan;
(eee) Phenomorphan;
(fff) Phenoperidine;
(fff)Phenoperidine;
(iii) Properidine;
(iii)roperidine;
HB 2828 4 (nnn) Tilidine;
(nnn) Tilidine;
(ooo) Trimeperidine;
HCS HB 2828 4 (ooo) Trimeperidine;
(5) Any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless HB 2828 5 specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(5) Any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(a) Alpha-ethyltryptamine;
HCS HB 2828 5 (a) Alpha-ethyltryptamine;
HB 2828 6 (ii) Peyote, to include all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not;
(ii) Peyote, to include all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not;
any extract from any part of such plant;
any extract from HCS HB 2828 6 any part of such plant;
(ll) Psilocybin;
(ll)Psilocybin;
(tt)Salvinorin A;
(tt) Salvinorin A;
(iii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;
(iii)JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;
HB 2828 7 (viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;
(viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;
(x) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
HCS HB 2828 7 (x) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
(iii)JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;
(iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;
Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, HB 2828 8 whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
(ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR-19 and RCS-4);
HCS HB 2828 8 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR-19 and RCS-4);
[(b)] (e) Mecloqualone;
[(b)](e) Mecloqualone;
(g) Nitrous oxide;
HB 2828 9 (k) Methylenedioxypyrovalerone, MDPV, or 1-(1,3-Benzodioxol-5-yl)-2-(1- pyrrolidinyl)-1-pentanone;
(k) Methylenedioxypyrovalerone, MDPV, or 1-(1,3-Benzodioxol-5-yl)-2-(1- pyrrolidinyl)-1-pentanone;
(l)Methylone, or 3,4-Methylenedioxymethcathinone;
(l) Methylone, or 3,4-Methylenedioxymethcathinone;
(o) N,N-dimethylamphetamine;
HCS HB 2828 9 (o) N,N-dimethylamphetamine;
HB 2828 10 (l) Pentylone, its optical, positional, and geometric isomers, salts, and salts of isomers;
(l) Pentylone, its optical, positional, and geometric isomers, salts, and salts of isomers;
(n) Alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers;
HCS HB 2828 10 (n) Alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers;
HB 2828 11 (dd) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;
(dd) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;
(ff) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;
HCS HB 2828 11 (ff) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;
HB 2828 12 (nn) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate, its optical, positional, and geometric isomers, salts, and salts of isomers (MMB-CHMICA, AMB-CHMICA);
(nn) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate, its optical, positional, and geometric isomers, salts, and salts of isomers (MMB-CHMICA, AMB-CHMICA);
(oo) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3- carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (5F- CUMYL-P7AICA);
HCS HB 2828 12 (oo) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3- carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (5F- CUMYL-P7AICA);
HB 2828 13 (aaa) 4'-chloro-alpha-pyrrolidinovalerophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:
(aaa) 4'-chloro-alpha-pyrrolidinovalerophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:
(9) Khat, to include all parts of the plant presently classified botanically as catha edulis, whether growing or not;
HCS HB 2828 13 (9) Khat, to include all parts of the plant presently classified botanically as catha edulis, whether growing or not;
Show all 83 changed rows (43 more)
Previous
Latest
(a) Opium and opiate;
(a)Opium and opiate;
j.
j.Etorphine hydrochloride;
Etorphine hydrochloride;
HB 2828 14 q.
q.
(b) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in this subdivision, but not including the isoquinoline alkaloids of opium;
HCS HB 2828 14 (b) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in this subdivision, but not including the isoquinoline alkaloids of opium;
HB 2828 15 (t) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
(t) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
(v) Phenazocine;
HCS HB 2828 15 (v) Phenazocine;
HB 2828 16 (7) Any material, compound, mixture, or preparation which contains any quantity of the following alkyl nitrites:
(7) Any material, compound, mixture, or preparation which contains any quantity of the following alkyl nitrites:
(a) Amyl nitrite;
HCS HB 2828 16 (a) Amyl nitrite;
(c) Any substance which contains any quantity of a derivative of barbituric acid or its salt;
(c)Any substance which contains any quantity of a derivative of barbituric acid or its salt;
HB 2828 17 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in a drug product for which an application has been approved under Section 505 of the federal Food, Drug, and Cosmetic Act;
(f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in a drug product for which an application has been approved under Section 505 of the federal Food, Drug, and Cosmetic Act;
(g) Ketamine, its salts, isomers, and salts of isomers;
HCS HB 2828 17 (g) Ketamine, its salts, isomers, and salts of isomers;
(e)Not more than five hundred milligrams of opium per one hundred milliliters or per one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts;
(e) Not more than five hundred milligrams of opium per one hundred milliliters or per one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts;
(f)Not more than fifty milligrams of morphine per one hundred milliliters or per one hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(f) Not more than fifty milligrams of morphine per one hundred milliliters or per one hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
Any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, HB 2828 18 and dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for that administration.
Any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for that HCS HB 2828 18 administration.
HB 2828 19 (cc) Methandienone (17α-methyl-17ß-hydroxyandrost-1,4-dien-3-one);
(cc) Methandienone (17α-methyl-17ß-hydroxyandrost-1,4-dien-3-one);
(ff) Methenolone (1-methyl-17ß-hydroxy-5α-androst-1-en-3-one);
HCS HB 2828 19 (ff) Methenolone (1-methyl-17ß-hydroxy-5α-androst-1-en-3-one);
(jj) 17α-methyl-4-hydroxynandrolone (17α-methyl-4-hydroxy-17β-hydroxyestr-4-en- 3-one);
(jj)17α-methyl-4-hydroxynandrolone (17α-methyl-4-hydroxy-17β-hydroxyestr-4-en- 3-one);
(rr) 19-nor-4-androstenediol (3α,17β-dihydroxyestr-4-ene);
(rr)19-nor-4-androstenediol (3α,17β-dihydroxyestr-4-ene);
(tt) 19-nor-5-androstenediol (3β,17β-dihydroxyestr-5-ene);
(tt)19-nor-5-androstenediol (3β,17β-dihydroxyestr-5-ene);
HB 2828 20 (iii) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
(iii) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
(jjj)Testosterone (17ß-hydroxyandrost-4-en-3-one);
(jjj) Testosterone (17ß-hydroxyandrost-4-en-3-one);
(lll)Trenbolone (17ß-hydroxyestr-4,9,11-trien-3-one);
HCS HB 2828 20 (lll) Trenbolone (17ß-hydroxyestr-4,9,11-trien-3-one);
HB 2828 21 (d) Any of the following limited quantities of narcotic drugs or their salts, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
(d) Any of the following limited quantities of narcotic drugs or their salts, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
a.
HCS HB 2828 21 a.
HB 2828 22 (x) Flurazepam;
(x) Flurazepam;
(bb) Ketazolam;
HCS HB 2828 22 (bb) Ketazolam;
(ll)Nimetazepam;
(ll) Nimetazepam;
HB 2828 23 (4) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:
(4) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:
(a) Cathine ((+)-norpseudoephedrine);
HCS HB 2828 23 (a) Cathine ((+)-norpseudoephedrine);
HB 2828 24 (1) The substance has low potential for abuse relative to the controlled substances listed in Schedule IV;
(1) The substance has low potential for abuse relative to the controlled substances listed in Schedule IV;
10.
HCS HB 2828 24 10.
Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1- HB 2828 25 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydro cannabinols.
Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1- methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydro cannabinols.
(1) All packages of any compound, mixture, or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind a pharmacy counter where the public is not permitted, and only by a registered pharmacist or registered pharmacy technician;
(1) All packages of any compound, mixture, or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or HCS HB 2828 25 ephedrine, its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind a pharmacy counter where the public is not permitted, and only by a registered pharmacist or registered pharmacy technician;
HB 2828 26 16.
16.
The scheduling of substances specified in subdivision (3) of subsection 10 of this section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds, mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound, mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.
The scheduling of substances specified in subdivision (3) of subsection 10 of this section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds, mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound, mixture, or preparation specified in subdivision (3) of subsection 10 of this HCS HB 2828 26 section which must be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.
HB 2828 27 [4.] 5.
[4.]5.
6.
HCS HB 2828 27 6.
[5.] 7.
[5.]7.
As used in this section, "psychoactive substance" means the substances listed in paragraphs (a), (b), (c), and (g) of subdivision (6) of subsection 1 of section 195.017.
As used in this section, "psychoactive substance" means the substances listed in paragraphs (a), (b), and (c) of subdivision (6) of subsection 2 of section 195.017.
or HB 2828 28 (2) The person knowingly permits a minor to purchase or transport illegally obtained controlled substances.
or (2) The person knowingly permits a minor to purchase or transport illegally obtained controlled substances.
7.
HCS HB 2828 28 7.
As used in this section, "psychoactive substance" means the substances listed in paragraphs (a), (b), (c), and (g) of subdivision (6) of subsection 1 of section 195.017.
As used in this section, "psychoactive substance" means the substances listed in paragraphs (a), (b), and (c) of subdivision (6) of subsection 2 of section 195.017.
⬇ Download PDF
View plain text versions (2)

Action History

  1. HCS Reported Do Pass (H) - AYES: 12 NOES: 0 PRESENT: 0

  2. HCS Voted Do Pass (H)

  3. Executive Session Completed (H)

  4. Public Hearing Completed (H)

  5. Public Hearing Scheduled, Bill not Heard (H)

  6. Referred: Emerging Issues(H)

  7. Read Second Time (H)

  8. Introduced and Read First Time (H)

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 3 co-sponsors · 195 not signed on

Sponsors (1)

Co-sponsors (3)

Not signed on (195)

195 members have not signed on to this bill.

Show all 195 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

Subjects

public-safety health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HB 2828?
HB 2828 is sponsored by Marty Joe Murray (Democratic), Ashley Aune (Democratic), Jaclyn Zimmermann (Democratic), and Elizabeth Fuchs (Democratic).
What is the current status of HB 2828?
This bill is in committee in the House. Introduced January 07, 2026. It must pass committee before a floor vote.
Where can I track HB 2828?
Track HB 2828 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 2828

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 2828

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →